Treatment options for C3 glomerulopathy
- 1 March 2013
- journal article
- case report
- Published by Wolters Kluwer Health in Current Opinion in Nephrology and Hypertension
- Vol. 22 (2) , 231-237
Abstract
Purpose of review The purpose of this review is to discuss emerging nomenclature, review the salient clinicopathological features and describe the therapeutic options available for the treatment of C3 glomerulopathy (C3G). Recent findings C3G is minimally responsive to traditional immune suppression and randomized controlled trials to support therapy are absent. The burgeoning understanding of the role of the alternative complement pathway in C3G combined with animal data supporting the use of terminal complement blockade and a few reports suggesting that the anticomplement drug eculizumab may offer a therapeutic advantage have triggered great interest in the field of complement-mediated renal disease. Summary Anticellular immune suppression and plasma therapy have limited efficacy in C3G. Data suggest that eculizumab may ameliorate disease in some C3G patients. The limited, recently published cohort data highlight crucial aspects of this group of diseases and support the need for extensive genetic and biomarker research to validate the pathologic mechanisms, delineate the spectrum of disease and guide the design of the rigorous trials to identify effective therapies for the treatment of C3G.Keywords
This publication has 39 references indexed in Scilit:
- Allelic Variants of Complement Genes Associated with Dense Deposit DiseaseJournal of the American Society of Nephrology, 2011
- Acute renal failure in dense deposit disease: complete recovery after combination therapy with immunosuppressant and plasma exchange.2011
- Recurrence of Complement Factor H-Related Protein 5 Nephropathy in a Renal TransplantAmerican Journal of Transplantation, 2011
- Human C3 mutation reveals a mechanism of dense deposit disease pathogenesis and provides insights into complement activation and regulationJournal of Clinical Investigation, 2010
- Defective complement control of Factor H (Y402H) and FHL-1 in age-related macular degenerationMolecular Immunology, 2007
- Dense deposit disease is not a membranoproliferative glomerulonephritisLaboratory Investigation, 2007
- Y402H Polymorphism of Complement Factor H Affects Binding Affinity to C-Reactive ProteinThe Journal of Immunology, 2007
- Primary glomerulonephritis with isolated C3 deposits: a new entity which shares common genetic risk factors with haemolytic uraemic syndromeJournal of Medical Genetics, 2006
- Prevention of C5 activation ameliorates spontaneous and experimental glomerulonephritis in factor H-deficient miceProceedings of the National Academy of Sciences, 2006
- Variations in the complement regulatory genes factor H (CFH) and factor H related 5 (CFHR5) are associated with membranoproliferative glomerulonephritis type II (dense deposit disease)Journal of Medical Genetics, 2005